Alzamend Neuro, Inc. (ALZN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Alzamend Neuro reported revenue of $0. Net income was -$8.8M, or -$2.63 per diluted share. Operating activities generated -$8.1M of cash. At fiscal year end, Alzamend Neuro held $2.1M in total assets against $1.3M in total liabilities, including $710,689 of cash and equivalents.
Open the full interactive Alzamend Neuro financials → Quarterly statements, key ratios, valuation history and price charts.
Alzamend Neuro Key Stats
| Share Price | $1.35 |
|---|---|
| Market Cap | $6.0M |
| 52-Week Range | $0.86 – $2.61 |
| Shares Outstanding | 4.5 million (basic, 2027 Q1) |
Alzamend Neuro Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$5.0M | -$12.3M | -$14.9M | -$9.9M | -$4.5M | -$8.8M |
| Pre-Tax Income | -$5.0M | -$12.4M | -$14.9M | -$9.9M | -$4.5M | -$8.8M |
| Income Tax | — | — | — | — | — | $1,101 |
| Net Income | -$5.0M | -$12.4M | -$14.9M | -$9.9M | -$4.5M | -$8.8M |
| Diluted EPS | -$94.50 | — | -$202.50 | -$132.30 | -$11.32 | -$2.63 |
Alzamend Neuro Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.0M | -$2.2M | -$2.9M | -$3.0M |
| Diluted EPS | -$0.30 | -$0.58 | -$0.86 | -$0.68 |
Alzamend Neuro Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.9M | $14.1M | $5.1M | $376,048 | $3.9M | $710,689 |
| Current Assets | $2.9M | $14.4M | $5.8M | $455,242 | $4.2M | $1.8M |
| Total Assets | $2.9M | $14.5M | $5.9M | $631,588 | $4.6M | $2.1M |
| Current Liabilities | $899,643 | $1.2M | $2.9M | — | — | — |
| Total Long-Term Debt | $335,303 | — | — | — | — | — |
| Total Liabilities | $899,643 | $1.2M | $2.9M | $3.2M | $634,761 | $1.3M |
| Shareholders' Equity | $2.0M | $13.4M | $3.0M | -$2.6M | $4.0M | $733,211 |
Alzamend Neuro Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$2.7M | -$6.6M | -$8.9M | -$8.3M | -$6.6M | -$8.1M |
| Cash From Investing | $100,915 | -$106,458 | — | -$147,243 | -$300,000 | — |
| Cash From Financing | $4.5M | $18.9M | $200 | $3.7M | $10.4M | $4.8M |
Figures from Alzamend Neuro's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Alzamend Neuro financials page for every line item.
Alzamend Neuro Company Profile
| Ticker | ALZN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Atlanta, Georgia |
| Incorporated in | Delaware |
| Fiscal Year End | April 30 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001677077 |
Frequently Asked Questions
What was Alzamend Neuro's revenue in fiscal 2026?
Alzamend Neuro (ALZN) reported revenue of $0 for fiscal 2026.
What is Alzamend Neuro's annual revenue history?
Alzamend Neuro's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0; 2026: $0.
What was Alzamend Neuro's net income in fiscal 2026?
Alzamend Neuro reported net income of -$8.8M for fiscal 2026.
What was Alzamend Neuro's earnings per share (EPS) in fiscal 2026?
Alzamend Neuro's diluted EPS was -$2.63 for fiscal 2026 (adjusted for any later stock splits).
What was Alzamend Neuro's revenue last quarter?
In its most recent reported quarter (2027 Q1), Alzamend Neuro reported revenue of $0.
How many shares of Alzamend Neuro are outstanding?
Alzamend Neuro reported a weighted average of 4.5 million basic shares outstanding in 2027 Q1.
What is Alzamend Neuro's market cap?
Based on its latest closing price, Alzamend Neuro (ALZN) has a market capitalization of about $6.0M.
When does Alzamend Neuro's fiscal year end?
Alzamend Neuro's fiscal year end, as registered with the SEC, is April 30.
Where is Alzamend Neuro headquartered?
Alzamend Neuro lists its business address in Atlanta, Georgia in its SEC filings.